Mulakan
ReutersReuters

Reviva To Present Negative Symptom Data For Brilaroxazine In Schizophrenia From Phase 3 Trials At CNS Summit 2025

RefinitivBacaan kurang dari 1 minit
RVPH

Reviva Pharmaceuticals Holdings Inc RVPH:

  • REVIVA TO PRESENT NEGATIVE SYMPTOM DATA FOR BRILAROXAZINE IN SCHIZOPHRENIA FROM THE PHASE 3 RECOVER DOUBLE-BLIND AND OPEN-LABEL EXTENSION TRIALS AT THE CNS SUMMIT 2025

ReutersSaham AS
refinitivrefinitiv
© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html
Log masuk atau cipta satu akaun percuma selamanya untuk membaca berita ini

Lebih berita dari Reuters